2 cheap growth stocks I’d buy for the long term

These two shares could offer a mix of growth and value in current market conditions.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Despite the recent pullback across the stock market, investor sentiment is generally upbeat. Certainly, the FTSE 100 has dropped by over 10% since its all-time high of a few months ago, but we are technically still in a bull market which could have further to run.

Therefore, buying stocks after the recent fall could be a wise move. They may offer greater volatility than expected, but their margins of safety now appear to be relatively wide. With that in mind, here are two stocks that could be worth a closer look today.

Improving outlook

Reporting on Monday was regenerative medical devices company Tissue Regenix (LSE: TRX). The performance of the business in 2017 was relatively encouraging, with its revenue increasing more than three-fold to £5.2m. It was able to launch additional product lines, addressing surgical reconstructive procedures and dental applications.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

The company’s £40m equity fundraise was successful and it was able to complete the acquisition of CellRight Technologies in August 2017. This has the potential to boost its financial performance over the medium term, with the stock expected to move into profitability in the next financial year. This follows a long period of lossmaking and could help to improve investor sentiment.

Although Tissue Regenix trades on a forward price-to-earnings (P/E) ratio of around 60, the company could deliver earnings growth in future years. It is entering a new phase of commercialisation which could produce a step-change in financial performance. As such, the company could prove to be a strong performer within what remains a relatively enticing wider healthcare industry.

Growth potential

Also offering upbeat investment potential is Hikma Pharmaceuticals (LSE: HIK). The company is in the midst of a challenging period which has seen its bottom line decline in each of the last three years. This has contributed to a fall in its share price of 45% in the last year. And with it due to report a further decline in its bottom line of 11% in the current year, its short-term performance could be somewhat disappointing.

However, over the medium term the company could experience an improvement in its share price performance. It is forecast to report a rise in earnings of 14% in the next financial year and this may lead to a change in investor sentiment. Since Hikma has a price-to-earnings growth (PEG) ratio of just 1.1, there seems to be significant upside potential on offer. As such, it could prove to be a strong turnaround play.

The healthcare industry could become increasingly popular in future. If the wider stock market remains volatile then investors may seek stocks that could offer lower positive correlation with the index. As such, buying Hikma right now could be a profitable move over the long run, while providing some protection against share price falls in the short run.

This AI stock is attracting investors like Michael Bloomberg and Peter Thiel…

Why are these legendary investors, already wealthy beyond imagination, drawn to this opportunity? The allure lies in more than just potential returns; it's a vote of confidence in a company poised for long-term success.

Imagine a revolutionary AI company that's not just participating in the digital media landscape but reshaping it entirely.

Trusted by giants like Amazon, Disney, and Netflix, the company reported nearly £637 million in revenue last year, marking a robust 7.8% growth over three years. Its impressive market reach and spirit of innovation are just the beginning of its story.

Best of all, we’re thrilled to offer you an exclusive glimpse into this game-changing AI investment, absolutely free.

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Hikma Pharmaceuticals. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Analysts have upgraded this FTSE 100 stock to Buy. What should investors do?

Associated British Foods shares have been uninspiring for some time. But is it finally time to consider buying the FTSE…

Read more »

Man changing battery on electric bicycle
Investing Articles

Prediction: in 12 months the sizzling National Grid share price could turn £10,000 into…

It's been another solid year for the National Grid share price and the dividend yield is decent too. So why…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 185% in 3 years, why does the market love this FTSE 250 stock

Over the past three years, this stock has vastly outperformed the FTSE 250. Dr James Fox takes a closer look…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing Articles

Looking for growth, dividends, or value? These 3 ETFs could be smart ideas to consider

Exchange-traded funds (ETFs) provide a way for investors to spread risk without sacrificing the possibility of huge long-term returns.

Read more »

Happy couple showing relief at news
Investing Articles

Is the Rolls-Royce share price fast becoming a joke?

The FTSE 100 engineering titan has done brilliantly in recent years. But our writer wonders whether the Rolls-Royce share price…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

Is there a ‘best age’ to start buying shares?

Christopher Ruane weighs some possible pros and cons of waiting to start buying shares for the first time, versus starting…

Read more »

piggy bank, searching with binoculars
Investing Articles

Is it time to look again at the FTSE 250’s worst performers?

Our writer considers the prospects for two of the worst-performing shares on the FTSE 250, with falls of at least…

Read more »

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing For Beginners

Down over 40% in the past year, I think investors should consider these value shares

Jon Smith points out two value shares that have fallen heavily over the past year but are starting to look…

Read more »